Philippe Peltier

Philippe has been a Partner at Auriga Partners since 1999. Philippe has been an early stage investor in numerous successful healthcare companies including Alantos Pharmaceuticals (acquired by Amgen), Innate Pharma (EuroNext Paris: IPH), Spine Next (acquired by Abbott), Targacept (Nasdaq: TRGT), Tigenix (EuroNext : TIG). He currently serves on the board of directors of several portfolio companies including, Novagali Pharma (France) and Genocea Biosciences (Etats-Unis). Prior to joining Auriga Partners, Philippe was an equity analyst with HSBC-CCF Securities, covering biotech and biopharma public stocks. He holds a MS in Molecular Biology from the University of Paris VII and a MS in finance from ESSEC (Paris).